BRPI0507763A - moduladores de receptor seletivo do subtipo gaba-a heterocìclicos - Google Patents

moduladores de receptor seletivo do subtipo gaba-a heterocìclicos

Info

Publication number
BRPI0507763A
BRPI0507763A BRPI0507763-0A BRPI0507763A BRPI0507763A BR PI0507763 A BRPI0507763 A BR PI0507763A BR PI0507763 A BRPI0507763 A BR PI0507763A BR PI0507763 A BRPI0507763 A BR PI0507763A
Authority
BR
Brazil
Prior art keywords
selective
heterocyclic
subtype
disorder
receptor modulators
Prior art date
Application number
BRPI0507763-0A
Other languages
English (en)
Inventor
David Garrett Loughhead
Sanja Novakovic
Counde O'yang
David George Putman
Michael Soth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0507763A publication Critical patent/BRPI0507763A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

MODULADORES DE RECEPTOR SELETIVO DO SUBTIPO GABA-A HETEROCìCLICOS. A invenção refere-se ao uso de compostos da fórmula (I) para a fabricação de um medicamento útil para modulação de receptores GABA~A~ do subtipo <244>~2~. A invenção refere-se ainda a compostos heterocíclicos e composições farmacêuticas contendo os ditos compostos. Ainda, a invenção refere-se ao tratamento de depressão, um distúrbio de ansiedade, um distúrbio psiquiátrico, um distúrbio de aprendizagem ou cognitivo, um distúrbio do sono, um distúrbio convulsivo ou de ataque ou dor.
BRPI0507763-0A 2004-02-18 2005-02-11 moduladores de receptor seletivo do subtipo gaba-a heterocìclicos BRPI0507763A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54552404P 2004-02-18 2004-02-18
PCT/EP2005/001406 WO2005077363A1 (en) 2004-02-18 2005-02-11 Heterocyclic gaba-a subtype selective receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0507763A true BRPI0507763A (pt) 2007-07-10

Family

ID=34860523

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507763-0A BRPI0507763A (pt) 2004-02-18 2005-02-11 moduladores de receptor seletivo do subtipo gaba-a heterocìclicos

Country Status (10)

Country Link
US (1) US7432283B2 (pt)
EP (1) EP1718299A1 (pt)
JP (1) JP2007523109A (pt)
KR (1) KR100820006B1 (pt)
CN (1) CN1921854A (pt)
AU (1) AU2005211920A1 (pt)
BR (1) BRPI0507763A (pt)
CA (1) CA2555287A1 (pt)
RU (1) RU2006133265A (pt)
WO (1) WO2005077363A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333680T3 (es) * 2006-04-11 2010-02-25 F. Hoffmann-La Roche Ag Moduladores heterociclicos del receptor selectivo del subtipo de gaba alfa.
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
JP2013506691A (ja) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド ホスファチジルイノシトール３−キナーゼのピラゾール阻害薬
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EP2886116A1 (en) * 2013-12-18 2015-06-24 Biocodex Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity
KR102161787B1 (ko) * 2018-07-02 2020-10-06 한국기초과학지원연구원 수면 장애의 예방 또는 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0674624T3 (da) * 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
US5705646A (en) * 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
US5668145A (en) * 1993-11-12 1997-09-16 Pfizer Inc. Amino-substituted pyrazoles having CRF antagonistic activity
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
US5760225A (en) * 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
GB9929685D0 (en) * 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
CA2404669A1 (en) * 2000-03-27 2001-10-04 Akiko Asakawa Condensed pyrazole derivatives, process for producing the same and use thereof
PL371049A1 (en) * 2001-12-04 2005-06-13 F.Hoffmann-La Roche Ag Ring fused pyrazole derivatives

Also Published As

Publication number Publication date
CN1921854A (zh) 2007-02-28
US7432283B2 (en) 2008-10-07
WO2005077363A1 (en) 2005-08-25
RU2006133265A (ru) 2008-04-10
KR100820006B1 (ko) 2008-04-08
CA2555287A1 (en) 2005-08-25
JP2007523109A (ja) 2007-08-16
KR20070029661A (ko) 2007-03-14
EP1718299A1 (en) 2006-11-08
US20050197330A1 (en) 2005-09-08
AU2005211920A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
BRPI0413540A (pt) moduladores gabanérgicos
UA94600C2 (en) Indole sulfonamide modulators of progesterone receptors
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
BR0312758A (pt) Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6
EA200970811A1 (ru) Новые производные бензамида в качестве модуляторов фолликулостимулирующего гормона
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
MA31889B1 (fr) N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci
EA200970342A1 (ru) Антагонисты рецептора глюкагона, композиции, содержащие такие соединения, и способы применения
WO2006031715A3 (en) Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
CO5680438A2 (es) Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
GEP20094844B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
CO6190616A2 (es) Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
NO20083481L (no) Tiofenyl- og pyrrolylazepiner som serotonin 5-HT2C-reseptorligander og anvendelser derav
GEP20094843B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
BRPI0412809A (pt) compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
BR0209047A (pt) Derivados de heterociclilalcóxi-, -alquiltio- e -alquilaminobenzazol como ligantes de 5-hidroxitriptamina-6
WO2008000692A3 (en) Pyrimidine and quinazoline derivatives as modulators of somatostatine receptor activity
DK1730147T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.